Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Photo of Niket Bubna
Person

Niket Bubna

Overview

Edit Overview Section
CB Rank (Person) 1,244,576
Niket Bubna joined KBI Biopharma as Associate Director in 2018.

Jobs

Edit Jobs Section
Number of Current Jobs 1
Niket Bubna is the Associate Director at KBI Biopharma.

Related Hubs

Edit Related Hubs Section
Hub Name  
CB Rank (Hub)  
Research Triangle Biotechnology Companies Logo
Research Triangle Biotechnology Companies
44,333
Research Triangle Companies With More Than $100M in Revenue Logo
Research Triangle Companies With More Than $100M in Revenue
99,257
North Carolina Companies With More Than $50M in Revenue Logo
North Carolina Companies With More Than $50M in Revenue
30,230
Research Triangle Companies With More Than $10M in Revenue Logo
Research Triangle Companies With More Than $10M in Revenue
38,163
North Carolina Health Care Companies Logo
North Carolina Health Care Companies
20,057
East Coast Biopharma Companies Logo
East Coast Biopharma Companies
17,637
Innovation Network Corporation of Japan Portfolio Companies Logo
Innovation Network Corporation of Japan Portfolio Companies
77,467
Research Triangle Companies With More Than $50M in Revenue Logo
Research Triangle Companies With More Than $50M in Revenue
99,443
North Carolina Manufacturing Companies Logo
North Carolina Manufacturing Companies
22,554
Research Triangle Investors Logo
Research Triangle Investors
56,023

Events

Edit Events Section
Number of Events 1
Niket Bubna has participated in 1 event, BioProcess International West 2017 on Feb 27, 2017.

Recent News and Activity

Edit Recent News and Activity Section
Number of News Articles 23
News•Apr 10, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 9, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 7, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 7, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 7, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 5, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 4, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 4, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 1, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 30, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
View All
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(411cf44 1)
|